These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


147 related items for PubMed ID: 29138505

  • 1. Increased Complement 3a Receptor is Associated with Behcet's disease and Vogt-Koyanagi-Harada disease.
    Wang C, Cao S, Zhang D, Li H, Kijlstra A, Yang P.
    Sci Rep; 2017 Nov 14; 7(1):15579. PubMed ID: 29138505
    [Abstract] [Full Text] [Related]

  • 2. Decreased expression of A20 is associated with ocular Behcet's disease (BD) but not with Vogt-Koyanagi-Harada (VKH) disease.
    He Y, Wang C, Su G, Deng B, Ye Z, Huang Y, Yuan G, Aize K, Li H, Yang P.
    Br J Ophthalmol; 2018 Aug 14; 102(8):1167-1172. PubMed ID: 29699987
    [Abstract] [Full Text] [Related]

  • 3. Copy number variations and gene polymorphisms of complement components in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome.
    Xu D, Hou S, Zhang J, Jiang Y, Kijlstra A, Yang P.
    Sci Rep; 2015 Aug 13; 5():12989. PubMed ID: 26269006
    [Abstract] [Full Text] [Related]

  • 4. Higher Expression of NOD1 and NOD2 is Associated with Vogt-Koyanagi-Harada (VKH) Syndrome But Not Behcet's Disease (BD).
    Deng B, Ye Z, Li L, Zhang D, Zhu Y, He Y, Wang C, Wu L, Kijlstra A, Yang P.
    Curr Mol Med; 2016 Aug 13; 16(4):424-35. PubMed ID: 26980698
    [Abstract] [Full Text] [Related]

  • 5. Activation of the liver X receptor inhibits Th17 and Th1 responses in Behcet's disease and Vogt-Koyanagi-Harada disease.
    Wu L, Wen H, Zhou Y, Yu H, Liu Y, Bai L, Kijlstra A, Yang P.
    Curr Mol Med; 2014 Aug 13; 14(6):712-22. PubMed ID: 25056541
    [Abstract] [Full Text] [Related]

  • 6. Decreased microRNA-155 expression in ocular Behcet's disease but not in Vogt Koyanagi Harada syndrome.
    Zhou Q, Xiao X, Wang C, Zhang X, Li F, Zhou Y, Kijlstra A, Yang P.
    Invest Ophthalmol Vis Sci; 2012 Aug 17; 53(9):5665-74. PubMed ID: 22815348
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-10 gene polymorphisms are associated with Behcet's disease but not with Vogt-Koyanagi-Harada syndrome in the Chinese Han population.
    Hu J, Hou S, Zhu X, Fang J, Zhou Y, Liu Y, Bai L, Kijlstra A, Yang P.
    Mol Vis; 2015 Aug 17; 21():589-603. PubMed ID: 26015771
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet's disease and Vogt-Koyanagi-Harada syndrome.
    Zhou Q, Hou S, Liang L, Li X, Tan X, Wei L, Lei B, Kijlstra A, Yang P.
    Ann Rheum Dis; 2014 Jan 17; 73(1):170-6. PubMed ID: 23268366
    [Abstract] [Full Text] [Related]

  • 9. Expression and role of interleukin-9 in Vogt-Koyanagi-Harada disease.
    Peng Z, Jiang S, Wu M, Zhou X, Wang Q.
    Mol Vis; 2017 Jan 17; 23():538-547. PubMed ID: 28761327
    [Abstract] [Full Text] [Related]

  • 10. TRAF5 and TRAF3IP2 gene polymorphisms are associated with Behçet's disease and Vogt-Koyanagi-Harada syndrome: a case-control study.
    Xiang Q, Chen L, Hou S, Fang J, Zhou Y, Bai L, Liu Y, Kijlstra A, Yang P.
    PLoS One; 2014 Jan 17; 9(1):e84214. PubMed ID: 24416204
    [Abstract] [Full Text] [Related]

  • 11. The role of interleukin-1 receptor-associated kinases in Vogt-Koyanagi-Harada disease.
    Sun M, Yang P, Du L, Yang Y, Ye J.
    PLoS One; 2014 Jan 17; 9(4):e93214. PubMed ID: 24690905
    [Abstract] [Full Text] [Related]

  • 12. miR-23a, miR-146a and miR-301a confer predisposition to Vogt-Koyanagi-Harada syndrome but not to Behcet's disease.
    Hou S, Ye Z, Liao D, Bai L, Liu Y, Zhang J, Kijlstra A, Yang P.
    Sci Rep; 2016 Jan 28; 6():20057. PubMed ID: 26818976
    [Abstract] [Full Text] [Related]

  • 13. A variant of CLEC16A gene confers protection for Vogt-Koyanagi-Harada syndrome but not for Behcet's disease in a Chinese Han population.
    Li K, Hou S, Qi J, Kijlstra A, Yang P.
    Exp Eye Res; 2015 Mar 28; 132():225-30. PubMed ID: 25576669
    [Abstract] [Full Text] [Related]

  • 14. Increased serum level of interleukin-33 in Vogt-Koyanagi-Harada correlates with disease activity.
    Qian Y, Yu R, Zhao C, Gao F, Zhang M.
    Clin Immunol; 2021 Oct 28; 231():108846. PubMed ID: 34478883
    [Abstract] [Full Text] [Related]

  • 15. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.
    Gu H, Fisher AJ, Mickler EA, Duerson F, Cummings OW, Peters-Golden M, Twigg HL, Woodruff TM, Wilkes DS, Vittal R.
    FASEB J; 2016 Jun 28; 30(6):2336-50. PubMed ID: 26956419
    [Abstract] [Full Text] [Related]

  • 16. Complement gene expression is regulated by pro-inflammatory cytokines and the anaphylatoxin C3a in human tenocytes.
    Busch C, Girke G, Kohl B, Stoll C, Lemke M, Krasnici S, Ertel W, Silawal S, John T, Schulze-Tanzil G.
    Mol Immunol; 2013 Apr 28; 53(4):363-73. PubMed ID: 23070120
    [Abstract] [Full Text] [Related]

  • 17. Increased IL-7 expression in Vogt-Koyanagi-Harada disease.
    Yang Y, Xiao X, Li F, Du L, Kijlstra A, Yang P.
    Invest Ophthalmol Vis Sci; 2012 Feb 27; 53(2):1012-7. PubMed ID: 22247488
    [Abstract] [Full Text] [Related]

  • 18. Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent Vogt-Koyanagi-Harada disease.
    Li F, Yang P, Liu X, Wang C, Hou S, Kijlstra A.
    Arch Ophthalmol; 2010 Nov 27; 128(11):1449-54. PubMed ID: 21060047
    [Abstract] [Full Text] [Related]

  • 19. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.
    Zhang Y, Yan X, Zhao T, Xu Q, Peng Q, Hu R, Quan S, Zhou Y, Xing G.
    Clin Exp Immunol; 2017 Jul 27; 189(1):60-70. PubMed ID: 28295247
    [Abstract] [Full Text] [Related]

  • 20. Genetic variations of IL17F and IL23A show associations with Behçet's disease and Vogt-Koyanagi-Harada syndrome.
    Hou S, Liao D, Zhang J, Fang J, Chen L, Qi J, Zhang Q, Liu Y, Bai L, Zhou Y, Kijlstra A, Yang P.
    Ophthalmology; 2015 Mar 27; 122(3):518-23. PubMed ID: 25439430
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.